- Report
- March 2022
- 142 Pages
Global
From €7239EUR$7,500USD£6,210GBP
- Report
- November 2020
- 101 Pages
Global
€21234EUR$22,000USD£18,215GBP
- Report
- June 2018
- 11 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- June 2018
- 11 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- June 2018
- 12 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- June 2018
- 546 Pages
Global
From €21234EUR$22,000USD£18,215GBP
- Report
- April 2022
- 330 Pages
Global
From €2413EUR$2,500USD£2,070GBP
Vascepa is a prescription drug used to reduce triglyceride levels in adults with severe hypertriglyceridemia. It is a purified form of the omega-3 fatty acid eicosapentaenoic acid (EPA). It is the first and only FDA-approved prescription omega-3 fatty acid for this indication. Vascepa is part of a class of cardiovascular drugs known as lipid-lowering agents, which are used to reduce the risk of cardiovascular disease. These drugs work by reducing the amount of cholesterol and triglycerides in the blood. Vascepa is also used to reduce the risk of cardiovascular events, such as heart attack and stroke, in adults with elevated triglyceride levels.
The Vascepa market is highly competitive, with several major pharmaceutical companies offering similar products. These include Amarin Corporation, AstraZeneca, GlaxoSmithKline, Merck & Co., and Pfizer. Show Less Read more